news – Page 34 – Medxy AI

Modulating Starch Digestibility: A Practical Strategy for Optimizing Glycemic Variability in Type 2 Diabetes

By MedXY 01/10/2026

A 12-week randomized controlled trial demonstrates that prioritizing slowly digestible starch (SDS) through dietary and culinary counseling significantly reduces glycemic variability and helps patients with type 2 diabetes achieve target HbA1c levels.

AI news Oncology Urology

Multimodal AI Outperforms Clinical Nomograms in Predicting Metastasis for Post-Prostatectomy Biochemical Recurrence

By MedXY 01/10/2026

A validated multimodal AI model using digital pathology and clinical data significantly improves risk stratification for prostate cancer patients with biochemical recurrence, identifying those who derive the greatest benefit from salvage hormone therapy.

Diabetes & Endocrinology Gastroenterology news

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial

By MedXY 01/10/2026

The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transformative approach for patients with metabolic-related liver disease.

Diabetes & Endocrinology Internal Medicine news

Breaking the C-Peptide Barrier: New Evidence Shows Automated Insulin Delivery Benefits All Adults with Type 2 Diabetes

By MedXY 01/10/2026

A landmark study reveals that automated insulin delivery systems significantly improve blood sugar control for adults with type 2 diabetes, regardless of their C-peptide levels, challenging current insurance restrictions that limit access to life-changing technology.

news Oncology Urology

Audit and Feedback in NMIBC Surgery: Improved Documentation Does Not Translate to Better Clinical Outcomes

By MedXY 01/10/2026

A global cluster randomized trial (RESECT) demonstrates that while audit and feedback improve surgical documentation in non-muscle-invasive bladder cancer, they fail to enhance detrusor muscle sampling, adjuvant chemotherapy use, or early recurrence rates.

news Oncology Urology

The NanoKnife Revolution: A Non-Thermal Leap Forward in Precision Prostate Cancer Care

By MedXY 01/10/2026

The PRESERVE trial demonstrates that Irreversible Electroporation (IRE) using the NanoKnife System is a safe and effective focal therapy for intermediate-risk prostate cancer, offering high success rates while preserving urinary and sexual health.

Cardiology Diabetes & Endocrinology news

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease

By MedXY 01/09/2026

Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved risk stratification beyond traditional clinical factors.

Clinical Updates news Oncology Urology

Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation

By MedXY 01/09/2026

This review synthesizes long-term outcomes and multiethnic data demonstrating that the Stockholm3 test significantly improves the detection of aggressive prostate cancer while reducing overdiagnosis and unnecessary procedures compared to traditional PSA-based screening.

news Oncology Respiratory

Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI

By MedXY 01/09/2026

This phase 1 trial identifies APG-2449 as a potent ALK/ROS1/FAK inhibitor. It shows significant efficacy in TKI-naïve and second-generation TKI-resistant ALK+ NSCLC, with high blood-brain barrier penetration and a manageable safety profile, offering a new strategy for managing treatment-resistant lung cancer.

Clinical Updates news Oncology

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

By MedXY 01/09/2026

The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.

news Oncology

Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results

By MedXY 01/09/2026

The final TROPION-Breast01 analysis confirms datopotamab deruxtecan's superior progression-free survival over chemotherapy in HR+/HER2- breast cancer. While overall survival did not reach significance, likely due to subsequent ADC crossover, the drug maintains a favorable safety profile and clinical utility.

news Oncology

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

By MedXY 01/09/2026

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-free survival and a manageable safety profile.

news Oncology Respiratory

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial

By MedXY 01/09/2026

The final analysis of the Phase III ALEX trial confirms alectinib's superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the first-line standard of care for ALK-positive advanced non-small cell lung cancer.

news Oncology

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

By MedXY 01/09/2026

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer compared to standard initiation protocols.

news Oncology Urology

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

By MedXY 01/09/2026

The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven therapy.

news Oncology

National Expertise and Molecular Profiling Extend Survival in Cancer of Unknown Primary: Insights from the French CUP MTB

By MedXY 01/09/2026

A French national study demonstrates that molecularly-guided treatments, facilitated by a dedicated multidisciplinary tumour board, significantly improve survival for patients with cancer of unknown primary, extending median overall survival from 11.0 to 18.6 months compared to empiric therapy.

news Oncology Pathology & Lab Medicine

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

By MedXY 01/09/2026

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression, identifying superior combination regimens for specific genomic subgroups.

Gastroenterology news Oncology

AXL: The Double-Edged Sword in Colorectal Cancer Treatment

By MedXY 01/09/2026

Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunotherapy, paving the way for more personalized oncology.

Clinical Updates news Oncology Pathology & Lab Medicine

Low-Pass Whole Genome Bisulfite Sequencing for ctDNA Monitoring in Metastatic Colorectal Cancer: Insights from the VALENTINO Trial

By MedXY 01/08/2026

This review evaluates the clinical utility of METER, a novel lp-WGBS workflow for ctDNA detection in RAS wild-type mCRC, demonstrating its prognostic value and cost-effectiveness in monitoring treatment response.

news Oncology

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

By MedXY 01/08/2026

The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resource-constrained healthcare settings.